BACKGROUND: The PET tracer (11)C-labeled Pittsburgh Compound-B ((11)C-PIB) specifically binds fibrillar amyloid-beta (Abeta) plaques and can be detected in Alzheimer disease (AD). We hypothesized that PET imaging with (11)C-PIB would discriminate AD from frontotemporal lobar degeneration (FTLD), a non-Abeta dementia. METHODS: Patients meeting research criteria for AD (n = 7) or FTLD (n = 12) and cognitively normal controls (n = 8) underwent PET imaging with (11)C-PIB (patients and controls) and (18)F-fluorodeoxyglucose ((18)F-FDG) (patients only). (11)C-PIB whole brain and region of interest (ROI) distribution volume ratios (DVR) were calculated using Logan graphical analysis with cerebellum as a reference region. DVR images were visually rated by a blinded investigator as positive or negative for cortical (11)C-PIB, and summed (18)F-FDG images were rated as consistent with AD or FTLD. RESULTS: All patients with AD (7/7) had positive (11)C-PIB scans by visual inspection, while 8/12 patients with FTLD and 7/8 controls had negative scans. Of the four PIB-positive patients with FTLD, two had (18)F-FDG scans that suggested AD, and two had (18)F-FDG scans suggestive of FTLD. Mean DVRs were higher in AD than in FTLD in whole brain, lateral frontal, precuneus, and lateral temporal cortex (p < 0.05), while DVRs in FTLD did not significantly differ from controls. CONCLUSIONS: PET imaging with (11)C-labeled Pittsburgh Compound-B ((11)C-PIB) helps discriminate Alzheimer disease (AD) from frontotemporal lobar degeneration (FTLD). Pathologic correlation is needed to determine whether patients with PIB-positive FTLD represent false positives, comorbid FTLD/AD pathology, or AD pathology mimicking an FTLD clinical syndrome.
BACKGROUND: The PET tracer (11)C-labeled Pittsburgh Compound-B ((11)C-PIB) specifically binds fibrillar amyloid-beta (Abeta) plaques and can be detected in Alzheimer disease (AD). We hypothesized that PET imaging with (11)C-PIB would discriminate AD from frontotemporal lobar degeneration (FTLD), a non-Abeta dementia. METHODS:Patients meeting research criteria for AD (n = 7) or FTLD (n = 12) and cognitively normal controls (n = 8) underwent PET imaging with (11)C-PIB (patients and controls) and (18)F-fluorodeoxyglucose ((18)F-FDG) (patients only). (11)C-PIB whole brain and region of interest (ROI) distribution volume ratios (DVR) were calculated using Logan graphical analysis with cerebellum as a reference region. DVR images were visually rated by a blinded investigator as positive or negative for cortical (11)C-PIB, and summed (18)F-FDG images were rated as consistent with AD or FTLD. RESULTS: All patients with AD (7/7) had positive (11)C-PIB scans by visual inspection, while 8/12 patients with FTLD and 7/8 controls had negative scans. Of the four PIB-positive patients with FTLD, two had (18)F-FDG scans that suggested AD, and two had (18)F-FDG scans suggestive of FTLD. Mean DVRs were higher in AD than in FTLD in whole brain, lateral frontal, precuneus, and lateral temporal cortex (p < 0.05), while DVRs in FTLD did not significantly differ from controls. CONCLUSIONS: PET imaging with (11)C-labeled Pittsburgh Compound-B ((11)C-PIB) helps discriminate Alzheimer disease (AD) from frontotemporal lobar degeneration (FTLD). Pathologic correlation is needed to determine whether patients with PIB-positive FTLD represent false positives, comorbid FTLD/AD pathology, or AD pathology mimicking an FTLD clinical syndrome.
Authors: Dustin Hammers; Elizabeth Spurgeon; Kelly Ryan; Carol Persad; Judith Heidebrink; Nancy Barbas; Roger Albin; Kirk Frey; David Darby; Bruno Giordani Journal: Am J Alzheimers Dis Other Demen Date: 2011-06-01 Impact factor: 2.035
Authors: Clifford R Jack; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Val Lowe; Kejal Kantarci; Matt A Bernstein; Matthew L Senjem; Jeffrey L Gunter; Bradley F Boeve; John Q Trojanowski; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; David S Knopman Journal: Arch Neurol Date: 2012-07
Authors: D P Devanand; Arthur Mikhno; Gregory H Pelton; Katrina Cuasay; Gnanavalli Pradhaban; J S Dileep Kumar; Neil Upton; Robert Lai; Roger N Gunn; V Libri; Xinhua Liu; Ronald van Heertum; J John Mann; Ramin V Parsey Journal: J Geriatr Psychiatry Neurol Date: 2010-04-29 Impact factor: 2.680
Authors: David A Wolk; Julie C Price; Charles Madeira; Judy A Saxton; Beth E Snitz; Oscar L Lopez; Chester A Mathis; William E Klunk; Steven T DeKosky Journal: Alzheimers Dement Date: 2012-01-30 Impact factor: 21.566
Authors: Gil D Rabinovici; William J Jagust; Ansgar J Furst; Jennifer M Ogar; Caroline A Racine; Elizabeth C Mormino; James P O'Neil; Rayhan A Lal; Nina F Dronkers; Bruce L Miller; Maria Luisa Gorno-Tempini Journal: Ann Neurol Date: 2008-10 Impact factor: 10.422
Authors: Gil D Rabinovici; Ansgar J Furst; Adi Alkalay; Caroline A Racine; James P O'Neil; Mustafa Janabi; Suzanne L Baker; Neha Agarwal; Stephen J Bonasera; Elizabeth C Mormino; Michael W Weiner; Maria L Gorno-Tempini; Howard J Rosen; Bruce L Miller; William J Jagust Journal: Brain Date: 2010-01-15 Impact factor: 13.501